Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410846 | 0.82 | EPHA2 (0.48) | HTR2AHTR2CHTR2BSIGMAR1EPHA2 | |
| SCHEMBL6408957 | 0.81 | HTR2C (0.61) | HTR2AHTR2CHTR2BEPHA2KDR | |
| SCHEMBL3783137 | 0.73 | HTR2C (1.00) | HTR2AHTR2CHTR2BSIGMAR1KCNH2 | |
| SCHEMBL6415399 | 0.70 | HTR2C (0.63) | HTR2AHTR2CHTR2BEPHA2KDR | |
| SCHEMBL17442409 | 0.69 | LTA4H (0.58) | HTR2AHTR2CHTR2BKDRTSHR | |
| SCHEMBL228313 | 0.69 | LTA4H (0.58) | HTR2AHTR2CHTR2BKDRTSHR | |
| SCHEMBL6413519 | 0.69 | LTA4H (0.58) | HTR2AHTR2CHTR2BKDRTSHR | |
| SCHEMBL467105 | 0.68 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL26469262 | 0.68 | HTR2A (0.50) | HTR2AHTR2CHTR2BSIGMAR1KDR | |
| SCHEMBL14426347 | 0.68 | LTA4H (0.59) | HTR2AHTR2CHTR2BKDM4ELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1465630-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | HTR2A 30/4885HTR2C 1/4885HTR2B 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.